Six doses. One rule. The Zepbound dosage schedule moves every patient up the same ladder: start at 2.5 mg once weekly, hold for four weeks, then climb in 2.5 mg steps until you settle at 5, 10, or 15 mg. The FDA label sets the pace, and the pace is strict — at least 4 weeks at every rung.
That schedule matters for more than side effects. It decides how fast results show up, and on cash menus it decides your bill, which runs roughly $299 to $449 a month by dose. Here is the whole ladder, explained.
Zepbound Dosage Schedule: The Full Ladder
Zepbound (tirzepatide) was approved by the FDA in November 2023 for chronic weight management. Its label is unusually specific about titration. You start low, and you climb on a timer.
Here is the fastest pace the label allows.
| Weeks on Zepbound | Dose (once weekly) | Role in the schedule |
|---|---|---|
| Weeks 1-4 | 2.5 mg | Starter dose — treatment initiation only |
| Weeks 5-8 | 5 mg | First approved maintenance dose |
| Weeks 9-12 | 7.5 mg | Step dose on the way up |
| Weeks 13-16 | 10 mg | Second approved maintenance dose |
| Weeks 17-20 | 12.5 mg | Step dose on the way up |
| Week 21+ | 15 mg | Maximum dose — final maintenance option |
Three things to notice. First, 7.5 mg and 12.5 mg are transition steps, not destinations — the approved maintenance doses for weight reduction are 5, 10, and 15 mg. Second, the fastest route to the top dose takes about 20 weeks, roughly 5 months. Third, four weeks is the minimum at each step, not a deadline. Plenty of prescribers hold patients at one dose for 8 or 12 weeks when it is working.
Every dose is injected under the skin of the abdomen, thigh, or back of the upper arm, on the same day each week. Pens and vials come in all six strengths, from 2.5 mg to 15 mg per injection.
Why Everyone Starts at 2.5 mg
The 2.5 mg starter dose is not really a treatment dose. Per the FDA label, it exists for treatment initiation — a four-week on-ramp that lets your gut adjust before the real dosing begins.
There is a good reason for the slow start. Tirzepatide activates two gut-hormone pathways at once — GLP-1 and GIP — and Cleveland Clinic notes that nausea, vomiting, and diarrhea are the most common side effects of this drug class. The SURMOUNT-1 trial confirmed the pattern: gastrointestinal side effects were the most frequent complaint, and they clustered during dose escalation, not after doses stabilized.
Translation: the climb is the hard part. The starter month buys tolerance cheaply. It is also literally the cheap month — telehealth cash menus verified in July 2026 list the 2.5 mg starter month at $299 before prices step up with dose.
Do not judge results by the first four weeks either. At 2.5 mg, appetite effects are real but modest. The trial numbers that made headlines — 15% to 20.9% average weight loss — came from maintenance doses held for 72 weeks.
The 4-Week Rule: Why You Cannot Rush the Climb
The label language is blunt. After 4 weeks at 2.5 mg, move to 5 mg. After that, doses may rise in 2.5 mg increments only after at least 4 weeks on the current dose. The ceiling is 15 mg once weekly — full stop.
Why no shortcuts? Because tolerance is dose-built. In SURMOUNT-1, side effects drove 4.3% of the 5 mg group, 7.1% of the 10 mg group, and 6.2% of the 15 mg group to quit the trial entirely. Rushing the ladder is how patients end up in those percentages.
The rule cuts the other way too. If a new dose hits you hard, the label says your prescriber can drop you back to the previous level and hold. Going backward is not failure — a lower maintenance dose you can stay on beats a higher dose you quit. About 4 to 7 patients in 100 quit tirzepatide over side effects in trials; the slow climbers are usually not among them.
One more piece of fine print: two doses must never land closer than 72 hours apart. That rule shapes everything about rescheduling, which we cover below.
What Each Dose Did in Trials
Higher doses earn more weight loss — but the gap between doses is smaller than most people expect. SURMOUNT-1, published in the New England Journal of Medicine, followed 2,539 adults for 72 weeks and split them across three maintenance doses and placebo.
| Maintenance dose | Average weight loss at 72 weeks | Lost at least 5% of body weight |
|---|---|---|
| 5 mg weekly | 15.0% | 85% |
| 10 mg weekly | 19.5% | 89% |
| 15 mg weekly | 20.9% | 91% |
| Placebo | 3.1% | 35% |
Read that table twice. The jump from 5 mg to 10 mg bought 4.5 extra percentage points of average weight loss. The jump from 10 mg to 15 mg bought just 1.4 more. That is why the label treats 5 mg and 10 mg as legitimate long-term doses, not consolation prizes.
These are trial averages over 72 weeks — not guarantees, and not everyone’s curve. Your response at 10 mg may beat someone else’s at 15 mg. The NIDDK also notes that prescription weight-loss medication works best alongside changes to eating and activity, which every trial arm above included.
How the Zepbound Dosage Schedule Changes Your Bill
Here is the part the label does not mention: on brand cash menus, titration is a price escalator.
Telehealth pricing verified in July 2026 lists the Zepbound KwikPen at $299 for the first month, then $399 to $449 per month as you move up — matching Lilly’s direct self-pay rates — plus a required membership of $39 the first month and $149 a month after. Hers lists Zepbound vials and KwikPens from $299 a month with its own $149 monthly membership, while retail pens on its menu run $1,899. The dose-by-dose math, membership fees included, is in our Zepbound cost without insurance breakdown.
Compounded tirzepatide plays by different pricing rules. bmiMD advertises the same price at every dose — $139 a month on a 12-month plan — and TrimRx promotes a flat $349 monthly promo across 2.5 mg to 15 mg, per pricing gathered in 2026. Flat pricing means titrating up costs you nothing extra.
But say it plainly: compounded tirzepatide is not FDA-approved. The FDA has published specific concerns about unapproved GLP-1 drugs, including dosing errors patients have made when drawing doses from multi-use vials — a real risk on a schedule with five dose changes. If you go that route anyway, our comparison of the best tirzepatide programs shows which vendors disclose their pharmacies and which hide the fine print.
Missed Doses, Day Switches, and Schedule Slips
Life happens to a weekly injection schedule. The label has an answer for every slip.
Missed a dose? Take it within 4 days — 96 hours — of when it was due. Past that window, skip it entirely and inject on your next regular day. Never take two doses to catch up.
Want to change your injection day? Fine, any day works — as long as the gap between two doses is at least 72 hours. Moving from Sunday to Friday means one short week of 5 days; that is allowed. Moving Sunday to Tuesday is not, because 48 hours is too close.
Traveling or delayed refill? The 96-hour grace window covers most shipping hiccups. If a refill delay stretches past a week or two, call your prescriber — after long gaps, some patients restart at a lower dose rather than resuming full strength, and that call belongs to a clinician, not a guess.
Missed weeks are not neutral. In trials, the results above came from 72 weeks of consistent weekly dosing. A schedule full of gaps quietly rewrites your expected curve.
Plateaus, Drop-Downs, and When to Switch
Around months 12 to 18, most patients see weight loss slow and level off. Even in SURMOUNT-1, curves flattened as the 72-week mark approached. A plateau on a maintenance dose is normal physiology, not proof your dose is broken.
You have three moves, in order. First, hold. If you are at 5 or 10 mg and maintaining a 15% loss, that is the medication doing its job. Second, step up — if you are below 15 mg and tolerating well, the next 2.5 mg rung is the label-sanctioned lever, after at least 4 weeks and with your prescriber’s sign-off. Third, step down or out. The label explicitly allows dropping to a lower maintenance dose when tolerability wins.
If you are already at 15 mg, plateaued, and unhappy — or side effects never settled — the conversation shifts from dose to drug. Semaglutide runs a completely different ladder, five steps to 2.4 mg over about 16 weeks; our Wegovy dosage schedule maps it rung by rung. And before you change molecules, read our guide to switching GLP-1 medications — switching mid-titration has its own rules, and getting them wrong usually means restarting a starter dose you already paid $299 to outgrow.
The schedule is the strategy. Four weeks a rung, 2.5 mg a step, 15 mg the hard ceiling — and no prize for finishing fastest.